For the 6–28% of rheumatoid arthritis (RA) patients who remain symptomatic despite treatment, inflammation may not be the whole story. Researchers at Semmelweis University, publishing in Nature Reviews Rheumatology and The Lancet Rheumatology, have identified a web of interconnected factors — depression, poor sleep, obesity, and smoking — that can independently sustain pain and fatigue even after inflammation is brought under control.

These factors don't just co-exist with RA; they can actively perpetuate it. Pain and depression reduce physical activity, which contributes to weight gain, which worsens sleep and mood, which amplifies pain — a vicious cycle that standard anti-inflammatory therapies may not break. The team's new model repurposes the existing "treat-to-target" framework as an early warning system: if inflammation markers improve but symptoms persist, it's a signal to look deeper rather than simply escalate medication.

Key Takeaways:

• If inflammation improves but pain and fatigue remain, non-inflammatory drivers — such as chronic pain syndrome, depression, sleep disorders, and obesity — should be investigated before changing medications
• The "difficult-to-treat" RA definition developed by this team has been cited over 1,000 times and is now applied across multiple disease areas globally
• AI-based pattern recognition is the team's next frontier, aiming to identify patient subgroups for more personalized treatment strategies

Why it matters: Unnecessary medication changes carry real risks and costs. By pinpointing the true drivers of persistent RA symptoms, clinicians can deliver more targeted, effective care — and potentially transform outcomes for the hardest-to-treat patients.